We want to develop novel strategies to stabilize vulnerable atherosclerotic plaques in carotid arteries. To achieve that, we utilize human material from the Munich Vascular Biobank as well as relevant clinical models and cell culture approaches. Main focus are molecular mechanisms and genetic factors that determine the fate of vascular smooth muscle cells within fibrous caps of advanced lesions. 

We use human biobank material, preclinical experimental models, and organoid systems (aorta-on-a-chip) to study the underlying patho-mechanisms of AAA disease. We develop novel models and treatment strategies to halt aneurysm progression.

such as microRNAS, long non-coding RNAs and circular RNAs, have recently been discovered to play crucial roles in cardiovascular homeostasis and disease development. We want to understand their deregulation and explore the therapeutic benefit of their modification.